Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.

Leong SR, Sukumaran S, Hristopoulos M, Totpal K, Stainton S, Lu E, Wong A, Tam L, Newman R, Vuillemenot BR, Ellerman D, Gu C, Mathieu M, Dennis MS, Nguyen A, Zheng B, Zhang C, Lee G, Chu YW, Prell RA, Lin K, Laing ST, Polson AG.

Blood. 2017 Feb 2;129(5):609-618. doi: 10.1182/blood-2016-08-735365. Epub 2016 Dec 1.

2.

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.

Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, Guenot J, Walter RB.

Clin Cancer Res. 2016 Dec 1;22(23):5829-5838. Epub 2016 May 17.

3.

Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.

Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, Wahl J, Hoffmann P, Kischel R, Kvesic M, Slootstra JW, Baeuerle PA, Kufer P, Rattel B.

Mol Cancer Ther. 2014 Jun;13(6):1549-57. doi: 10.1158/1535-7163.MCT-13-0956. Epub 2014 Mar 27.

4.

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.

Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, Henn A, Rattel B, Friedrich M, Baeuerle PA, Mackensen A, Krause SW.

Leukemia. 2013 Apr;27(5):1107-15. doi: 10.1038/leu.2012.341. Epub 2012 Nov 26.

PMID:
23178753
5.

Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

Lu H, Zhou Q, Deshmukh V, Phull H, Ma J, Tardif V, Naik RR, Bouvard C, Zhang Y, Choi S, Lawson BR, Zhu S, Kim CH, Schultz PG.

Angew Chem Int Ed Engl. 2014 Sep 8;53(37):9841-5. doi: 10.1002/anie.201405353. Epub 2014 Jul 23.

6.

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.

Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, Mai E, Young J, Johnson C, Huseni M, Wang X, Chen Y, Wang P, Wang H, Dybdal N, Chu YW, Chiorazzi N, Scheer JM, Junttila T, Totpal K, Dennis MS, Ebens AJ.

Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802.

PMID:
25972002
7.

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.

Zugmaier G, Klinger M, Schmidt M, Subklewe M.

Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13. Review.

PMID:
25883042
8.

Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.

Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I, Stamova S, Bornhäuser M, Schmitz M, Ehninger G, Bachmann M.

Leukemia. 2013 Apr;27(4):964-7. doi: 10.1038/leu.2013.18. Epub 2013 Jan 17. No abstract available.

PMID:
23325142
9.

Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.

Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS.

Int J Mol Sci. 2017 Oct 27;18(11). pii: E2259. doi: 10.3390/ijms18112259.

10.

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.

11.

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.

Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, von Bonin M, Ehninger A, Bachmann J, Ehninger G, Bornhäuser M, Bachmann MP.

Blood Cancer J. 2015 Sep 18;5:e348. doi: 10.1038/bcj.2015.73.

12.

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, Kischel R, Chen G, Walter RB.

PLoS One. 2015 Aug 25;10(8):e0135945. doi: 10.1371/journal.pone.0135945. eCollection 2015.

13.

Acute myeloid leukemia targets for bispecific antibodies.

Hoseini SS, Cheung NK.

Blood Cancer J. 2017 Feb 3;7(2):e522. doi: 10.1038/bcj.2017.2. Review. Erratum in: Blood Cancer J. 2017 Apr 14;7(4):e552.

14.

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.

Blood. 2016 Jan 7;127(1):122-31. doi: 10.1182/blood-2014-05-575704. Epub 2015 Nov 3.

15.

The role of CD33 as therapeutic target in acute myeloid leukemia.

Walter RB.

Expert Opin Ther Targets. 2014 Jul;18(7):715-8. doi: 10.1517/14728222.2014.909413. Epub 2014 Apr 21.

PMID:
24750020
16.

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.

Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, Topp M, Little M, Zhukovsky EA.

MAbs. 2015;7(3):584-604. doi: 10.1080/19420862.2015.1029216.

17.

An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.

Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J.

Sci Transl Med. 2017 Oct 4;9(410). pii: eaal4291. doi: 10.1126/scitranslmed.aal4291.

PMID:
28978751
18.

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.

Laszlo GS, Gudgeon CJ, Harrington KH, Walter RB.

Blood Cancer J. 2015 Aug 21;5:e340. doi: 10.1038/bcj.2015.68.

19.

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB.

Blood. 2014 Jan 23;123(4):554-61. doi: 10.1182/blood-2013-09-527044. Epub 2013 Dec 5.

20.

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S.

Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27.

Supplemental Content

Support Center